As ibrutinib and other BCR-directed therapies are being rapidly incorporated into CLL treatment armamentarium, understanding how UM and M-CLL differ biologically and whether ibrutinib perturbs these cells in similar or different manners may be clinically relevant. This evidence concerns the gene BCR and B-cell chronic lymphocytic leukemia.